相关实验视频

Updated: May 6, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

基于图像的表型分析能够快速准确地评估肺癌患者组织中的EGFR激活突变

Qian Lei^1,2,3, Xinglong Zhou⁴, Ying Li^1,2,3

¹Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610065, China.

Journal of the American Chemical Society

|January 2, 2025

概括

一种新的成像探针可以识别肺癌细胞和瘤中的表皮生长因子受体 (EGFR) 突变. 这种基于药物的方法为指导EGFR氨酸激酶抑制剂 (TKI) 治疗提供了更快,更准确的方法.

科学领域:

生物医学成像
分子瘤学
药物发现

背景情况:

精确识别表皮生长因子受体 (EGFR) 突变对于肺癌中有效的EGFR氨酸激酶抑制剂 (TKI) 治疗至关重要.
目前的DNA测序方法耗时,提供有限的信息,阻碍了最佳治疗策略的设计.

研究的目的:

开发一种基于图像的新方法,用于快速和具体检测突变EGFR蛋白质.
实现活细胞和瘤EGFR突变的实时可视化和表型评估.
为指导肺癌EGFR-TKI治疗的治疗决策.

主要方法:

基于EGFR-TKI的灭,共价准探针的合理设计.
在活细胞中实时成像EGFR的"无洗"探针的应用.
基于光强度的成像,以区分EGFR突变与野生类型瘤.
与免疫组织化学的整合提高了诊断的准确性.

主要成果:

探测器专门针对活细胞中的突变EGFR.
在突变型瘤与野生型瘤的区别方面实现了高信号对比度.
在肺癌患者中以图像为基础预测EGFR突变,准确度为94%.
当与免疫组织化学结合时,准确度提高到98%.

结论:

一种基于药物的表型成像方法使EGFR突变在活检中可视化.
这种方法有效地定义了EGFR突变组以指导EGFR-TKI治疗.
这种方法补充了用于个性化肺癌治疗的传统基因突变分析.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...